VX-702

Base Information

• Chemical Name: VX-702
• CAS No.: 745833-23-2
• Molecular Formula: C19H12F4N4O2
• Molecular Weight: 404.323
• Hs Code.: 2933399990
• European Community (EC) Number: 833-998-9
• UNII: 527E7SK68P
• DSSTox Substance ID: DTXSID50963974
• Nikkaji Number: J3.392.005I
• Wikidata: Q27089207
• Pharos Ligand ID: W8KL9Y648AF4
• Metabolomics Workbench ID: 149487
• ChEMBL ID: CHEMBL1090090
• Mol file: 745833-23-2 .mol

Synonyms:KVK 702;KVK-702;KVK702;VX 702;VX 850;VX 954;VX-702;VX-850;VX-954;VX702 cpd;VX805 cpd;VX954 cpd

Chemical Property of VX-702

Chemical Property:

• Boiling Point: 555.2±60.0 °C(Predicted)
• PKA: 10.65±0.50(Predicted)
• PSA: 102.31000
• Density: 1.503
• LogP: 5.02130
• Storage Temp.: -20°C
• Solubility.: Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 2 mg/ml)
• XLogP3: 2.5
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 4
• Exact Mass: 404.08963829
• Heavy Atom Count: 29
• Complexity: 603

Purity/Quality:

99% ^*data from raw suppliers

VX-702 ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F
• Recent ClinicalTrials: Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
• Recent EU Clinical Trials: A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 when Administered Concomitantly with Methotrexate
• Description: VX-702 is a third generation inhibitor of p38 mitogen-activated protein (MAP) kinases, binding to both p38α and p38β (Kd = 3.7 and 17 nM, respectively) in an ATP-competitive fashion. It inhibits IL-6, IL-1β, and TNF-α production in LPS-primed blood with IC50 values of 59, 122, and 99 ng/ml, respectively. VX-702, at 1 μM, inhibits activation of p38 in platelets by thrombin, U-46619 , or collagen but does not block platelet aggregation in response to collagen. Although orally active, VX-702 provides only transient suppression of biomarkers of inflammation in ongoing rheumatoid arthritis.
• Uses: VX-702 is a p38 mitogen-activated protein kinase (MAPK) inhibitor. VX-702 had no effect on platelet aggregation induced by any of the p38 MAPK agonists. VX-702 has potential use in the treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. VX-702 is a third generation inhibitor of p38 mitogen-activated protein (MAP) kinases, binding to both p38α and p38β (Kd = 3.7 and 17 nM, respectively) in an ATP-competitive fashion. It inhibits IL-6, IL-1β, and TNF-α production in LPS-primed blood with IC50 values of 59, 122, and 99 ng/ml, respectively. VX-702, at 1 μM, inhibits activation of p38 in platelets by thrombin, U-46619 , or collagen but does not block platelet aggregation in response to collagen. Although orally active, VX-702 provides only transient suppression of biomarkers of inflammation in ongoing rheumatoid arthritis.[Cayman Chemical]

Technology Process of VX-702

There total 1 articles about VX-702 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

2-(2,4-difluorophenyl)-6-(2,6-difluorophenylamino)nicotinic acid + bis(trichloromethyl) carbonate (32315-10-9) → VX 702 (745833-23-2,479543-46-9)

Guidance literature:

2-(2,4-difluorophenyl)-6-(2,6-difluorophenylamino)nicotinic acid; bis(trichloromethyl) carbonate; With N-ethyl-N,N-diisopropylamine; In tetrahydrofuran; at -35 - 20 ℃;

With ammonia; In tetrahydrofuran; at -30 ℃;

upstream raw materials:

bis(trichloromethyl) carbonate

Refernces

• 1、 -. "PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES)". Page/Page column 26. . Retrieved 2010/09/03.